Sibutramine Cardiovascular Outcomes - SCOUT

Description:

The goal of the trial was to evaluate treatment with the weight loss agent sibutramine (Meridia) compared with placebo among obese individuals.

Sibutramine is a norepinephrine and serotonin reuptake inhibitor; therefore, it has sympathomimetic effects.